Overall Survival in TP53-mutated AML and MDS

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Oct 23

PMID 39443370

Authors

Christian J Puzo

Karl M Hager

Henry M Rinder

Olga K Weinberg

Alexa J Siddon

Affiliations

Soon will be listed here.

Abstract

TP53 mutations in patients with AML and MDS frequently portend a poor prognosis, related to both p53 allele status and blast count. In 2022, the ICC and WHO released updated guidelines for classifying p53-mutated AML/MDS. The characteristics of p53 mutations, their associated co-mutations, and their effects on overall survival (OS) are not known in the context of these new guidelines. A retrospective chart review was undertaken for all patients with AML or MDS and at least one TP53 mutation detected on next generation sequencing (NGS) at Yale New Haven Hospital from 2015 to 2023. All patients (N = 210) met criteria for one of the 5 diagnostic classes based on WHO and ICC guidelines. Kaplan-Meier curves with associated log-rank testing and Cox proportional hazards model quantified the effects of clinical and molecular data on survival. Multi-hit pathogenic mutations were related to poorer OS in MDS but not AML using either the WHO (p = .02) or the ICC (p = .01) diagnostic criteria. The most significant predictors of OS in the sample overall were platelet count < 50 K (HR: 2.01, 95% CI [1.47, 2.75], p < .001) and TP53 VAF ≤ 40% (HR: 0.68, 95% CI[0.50, 0.91], p = .01). Blast count ranges, complex karyotype, and p53 mutation type or location, showed no association with OS. In our cohort defined by the 2022 ICC and WHO criteria, VAF and thrombocytopenia, rather than blast count or p53 mutation features, significantly predicted OS. These results speak to each criteria's ability to identify cases of similarly aggressive disease biology and prognosis.

References

Sebaa A, Ades L, Baran-Marzack F, Mozziconacci M, Penther D, Dobbelstein S . Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012; 51(12):1086-92. DOI: 10.1002/gcc.21993. View

Zhang L, McGraw K, Sallman D, List A . The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leuk Lymphoma. 2016; 58(8):1777-1790. DOI: 10.1080/10428194.2016.1266625. View

Hunter A, Sallman D . Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019; 32(2):134-144. DOI: 10.1016/j.beha.2019.05.004. View

DiNardo C, Tiong I, Quaglieri A, MacRaild S, Loghavi S, Brown F . Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803. PMC: 7068032. DOI: 10.1182/blood.2019003988. View

Li X, Xu F, Wu L, Guo J, He Q, Zhang Z . Somatic mutations in SF3B1 aberrant-negative MDS-RS most commonly involved in TP53 genes. J Cell Mol Med. 2022; 26(12):3586-3589. PMC: 9189334. DOI: 10.1111/jcmm.17350. View

Fang K, Qi J, Zhou M, Zhang Z, Han Y . Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2021; 22(4):224-235. DOI: 10.1016/j.clml.2021.09.013. View

Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E . Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol. 2021; 39(11):1223-1233. PMC: 8078359. DOI: 10.1200/JCO.20.01659. View

Weinberg O, Siddon A, Madanat Y, Gagan J, Arber D, Dal Cin P . TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022; 6(9):2847-2853. PMC: 9092405. DOI: 10.1182/bloodadvances.2021006239. View

Bernard E, Nannya Y, Hasserjian R, Devlin S, Tuechler H, Medina-Martinez J . Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020; 26(10):1549-1556. PMC: 8381722. DOI: 10.1038/s41591-020-1008-z. View

10.

Daver N, Maiti A, Kadia T, Vyas P, Majeti R, Wei A . TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022; 12(11):2516-2529. PMC: 9627130. DOI: 10.1158/2159-8290.CD-22-0332. View

11.

Boettcher S, Miller P, Sharma R, McConkey M, Leventhal M, Krivtsov A . A dominant-negative effect drives selection of missense mutations in myeloid malignancies. Science. 2019; 365(6453):599-604. PMC: 7327437. DOI: 10.1126/science.aax3649. View

12.

Stengel A, Meggendorfer M, Walter W, Baer C, Nadarajah N, Hutter S . Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS. Blood Adv. 2023; 7(18):5540-5548. PMC: 10515307. DOI: 10.1182/bloodadvances.2023010312. View

13.

Grob T, Al Hinai A, Sanders M, Kavelaars F, Rijken M, Gradowska P . Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022; 139(15):2347-2354. PMC: 11022827. DOI: 10.1182/blood.2021014472. View

14.

Fleti F, Chan O, Singh A, Abdelmagid M, Al-Kali A, Elliott M . TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023; 98(4):E76-E79. DOI: 10.1002/ajh.26845. View

15.

Sallman D, Komrokji R, Vaupel C, Cluzeau T, Geyer S, McGraw K . Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2015; 30(3):666-73. PMC: 7864381. DOI: 10.1038/leu.2015.304. View

16.

Sabapathy K, Lane D . Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2017; 15(1):13-30. DOI: 10.1038/nrclinonc.2017.151. View

17.

Baugh E, Ke H, Levine A, Bonneau R, Chan C . Why are there hotspot mutations in the TP53 gene in human cancers?. Cell Death Differ. 2017; 25(1):154-160. PMC: 5729536. DOI: 10.1038/cdd.2017.180. View

18.

Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A . A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation. Mol Cell. 2018; 71(1):178-190.e8. DOI: 10.1016/j.molcel.2018.06.012. View

19.

Giacomelli A, Yang X, Lintner R, McFarland J, Duby M, Kim J . Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018; 50(10):1381-1387. PMC: 6168352. DOI: 10.1038/s41588-018-0204-y. View

20.

Dutta S, Moritz J, Pregartner G, Thallinger G, Brandstatter I, Lind K . Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations. Ann Hematol. 2022; 101(4):837-846. PMC: 8913568. DOI: 10.1007/s00277-022-04766-2. View